EA038285B9 - Происходящее от человека антитело к дипептидным повторам (dpr) - Google Patents

Происходящее от человека антитело к дипептидным повторам (dpr)

Info

Publication number
EA038285B9
EA038285B9 EA201790433A EA201790433A EA038285B9 EA 038285 B9 EA038285 B9 EA 038285B9 EA 201790433 A EA201790433 A EA 201790433A EA 201790433 A EA201790433 A EA 201790433A EA 038285 B9 EA038285 B9 EA 038285B9
Authority
EA
Eurasian Patent Office
Prior art keywords
dpr
antibodies
antigen binding
binding fragments
c9orf72
Prior art date
Application number
EA201790433A
Other languages
English (en)
Other versions
EA201790433A1 (ru
EA038285B1 (ru
Inventor
Фабио Монтрасио
Ян Гримм
Original Assignee
Нейриммьюн Холдинг Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нейриммьюн Холдинг Аг filed Critical Нейриммьюн Холдинг Аг
Priority claimed from PCT/EP2015/072516 external-priority patent/WO2016050822A2/en
Publication of EA201790433A1 publication Critical patent/EA201790433A1/ru
Publication of EA038285B1 publication Critical patent/EA038285B1/ru
Publication of EA038285B9 publication Critical patent/EA038285B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025—Nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

В изобретении предложены новые антитела человека и антигенсвязывающие фрагменты указанных антител, которые связываются с белком, содержащим дипептидный повтор (DPR-белок) поли-глицин-аланин (GA)15, транслируемый с открытой рамки считывания 72 (C9ORF72) хромосомы 9, а также полинуклеотиды, экспрессионные векторы и клетки хозяева для получения антител и антигенсвязывающих фрагментов согласно настоящему изобретению. Кроме того, предложены фармацевтические композиции, содержащие антитела или антигенсвязывающие фрагменты согласно настоящему изобретению, предназначенные для иммунотерапевтического лечения, профилактики или диагностики заболеваний или расстройств, связанных с DPR-белками и/или агрегатами C9ORF72, а также соответствующие способы. В область изобретения также включены способы получения антител и антигенсвязывающих фрагментов согласно настоящему изобретению и количественные способы детекции in vivo белка, содержащие дипептидный повтор (DPR) поли-глицин-аланин (GA) у субъекта, такой как C9ORF72.
EA201790433A 2015-08-07 2015-09-30 Происходящее от человека антитело к дипептидным повторам (dpr) EA038285B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15180310 2015-08-07
PCT/EP2015/072516 WO2016050822A2 (en) 2014-09-30 2015-09-30 Human-derived anti-dipeptide repeats (dprs) antibody

Publications (3)

Publication Number Publication Date
EA201790433A1 EA201790433A1 (ru) 2017-09-29
EA038285B1 EA038285B1 (ru) 2021-08-04
EA038285B9 true EA038285B9 (ru) 2022-03-10

Family

ID=53783654

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201790433A EA038285B9 (ru) 2015-08-07 2015-09-30 Происходящее от человека антитело к дипептидным повторам (dpr)
EA202092790A EA202092790A1 (ru) 2015-08-07 2015-09-30 Происходящее от человека антитело к дипептидным повторам (dpr)

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202092790A EA202092790A1 (ru) 2015-08-07 2015-09-30 Происходящее от человека антитело к дипептидным повторам (dpr)

Country Status (1)

Country Link
EA (2) EA038285B9 (ru)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014114303A1 (en) * 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
US9448232B2 (en) * 2013-01-24 2016-09-20 Mayo Foundation For Medical Education And Research Methods and materials for detecting C9ORF72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or C9ORF72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
EA202092790A1 (ru) 2021-07-30
EA201790433A1 (ru) 2017-09-29
EA038285B1 (ru) 2021-08-04

Similar Documents

Publication Publication Date Title
MX2021011697A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123.
MX2022015821A (es) Nuevos receptores de celulas t y usos de los mismos.
MX2019006727A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
MX2019006724A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
JO3711B1 (ar) أجسام مضادة محددة لبروتين تاو وطرق استعمالها
PH12017500489A1 (en) Human-derived anti-dipeptide repeats (dprs) antibody
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
PH12017500331A1 (en) Antigen binding proteins that bind cxcr5
PH12019500571A1 (en) Anti-pd-1 antibodies
MX2020011312A (es) Anticuerpo de repetición de dipéptidos (dpr) anti poliglicina-alanina (poli-ga) derivado de humanos.
MX2017001285A (es) Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
MX2021010281A (es) Proteinas de enlace a antigenos que se enlazan al bcma.
PH12017500332A1 (en) Antigen binding proteins that bind cxcr3
MX2019013211A (es) Proteinas de union al antigeno anti-jagged1.
EP3974443A3 (en) Peptides derived from melanoma-associated antigen b2 (mageb2)
EA038285B9 (ru) Происходящее от человека антитело к дипептидным повторам (dpr)
WO2017089781A3 (en) Peptides derived from abnormal spindle-like microcephaly-associated protein (aspm) and complexes comprising such peptides bound to mhc molecules
WO2016040767A3 (en) Chrdl-1 epitopes and antibodies
PH12019501263A1 (en) Novel t cell receptors and immune therapy using the same

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent